Through leveraging gene signatures in predicting the durability of drug response, this study also identified the expression levels of the genes MMP2, SPARC, and HMOX1 as having a good predictive value in predicting the emergence of chemoresistance to BRAF/MEK inhibitor therapy in melanomas. The gene discussed is BRAF; the disease is melanoma.